Role of protein flexibility in the design of Bcl-X(L) targeting agents: insight from molecular dynamics.
Detailed understanding of protein-ligand interactions is crucial to the design of more effective drugs. This is particularly true when targets are protein interfaces which have flexible, shallow binding sites that exhibit substantial structural rearrangement upon ligand binding. In this study, we use molecular dynamics simulations and free energy calculations to explore the role of ligand-induced conformational changes in modulating the activity of three generations of Bcl-X(L) inhibitors. We show that the improvement in the binding affinity of each successive ligand design is directly related to a unique and measurable reduction in local flexibility of specific regions of the binding groove, accompanied by the corresponding changes in the secondary structure of the protein. Dynamic analysis of ligand-protein interactions reveals that the latter evolve with each new design consistent with the observed increase in protein stability, and correlate well with the measured binding affinities. Moreover, our free energy calculations predict binding affinities which are in qualitative agreement with experiment, and indicate that hydrogen bonding to Asn100 could play a prominent role in stabilizing the bound conformations of latter generation ligands, which has not been recognized previously. Overall our results suggest that molecular dynamics simulations provide important information on the dynamics of ligand-protein interactions that can be useful in guiding the design of small-molecule inhibitors of protein interfaces.
Novak
William
W
Department of Chemistry, Boston College, 2609 Beacon Street, Chestnut Hill, MA 02135, USA.
Wang
Hongming
H
Krilov
Goran
G
D015195:Drug Design; D008024:Ligands; D008958:Models, Molecular; D011487:Protein Conformation; D051020:bcl-X Protein / Q000737:chemistry* / Q000187:drug effects*
D008024:Ligands; D051020:bcl-X Protein
Nature. 2005 Jun 2;435(7042):677-81
15902208
J Med Chem. 2006 Feb 9;49(3):1165-81
16451081
Nat Rev Drug Discov. 2004 Apr;3(4):301-17
15060526
Science. 1997 Feb 14;275(5302):983-6
9020082
Protein Sci. 2000 Dec;9(12):2528-34
11206074
J Med Chem. 2007 Feb 22;50(4):641-62
17256834
Angew Chem Int Ed Engl. 2005 Jul 4;44(27):4130-63
15954154
Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49
14996506
Science. 1996 Nov 29;274(5292):1531-4
8929414
Bioorg Med Chem. 2007 Oct 1;15(19):6407-17
17629704
Semin Cancer Biol. 2003 Apr;13(2):115-23
12654255
Curr Med Chem Anticancer Agents. 2002 Mar;2(2):311-30
12678748
Cancer Cell. 2002 Feb;1(1):19-30
12086884
Mol Immunol. 2003 Jan;39(11):615-47
12493639
J Med Chem. 2006 Jan 26;49(2):656-63
16420051
J Am Chem Soc. 2006 Dec 20;128(50):16206-12
17165773
Cancer Res. 2000 Nov 1;60(21):6101-10
11085534
J Med Chem. 2007 Jul 26;50(15):3457-64
17602601
J Comput Chem. 2005 Dec;26(16):1701-18
16211538
J Biol Chem. 1998 Jun 19;273(25):15458-63
9624131
J Am Chem Soc. 2002 Feb 20;124(7):1234-40
11841292
J Cell Biochem. 2006 Sep 1;99(1):305-18
16619258
J Comput Aided Mol Des. 2004 Jan;18(1):13-22
15143800
J Mol Biol. 2007 Aug 24;371(4):1099-117
17597151
Phys Rev A Gen Phys. 1985 Mar;31(3):1695-1697
9895674
Cell Res. 2006 Feb;16(2):203-13
16474435
Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94
14996493
J Biol Chem. 2004 Jan 16;279(3):2159-65
14534311
Nat Rev Cancer. 2002 Sep;2(9):647-56
12209154
Angew Chem Int Ed Engl. 2003 Jun 6;42(22):2462-81
12800163
Nature. 1996 May 23;381(6580):335-41
8692274